Dr. Mike Poole, vice president of the AstraZenecaNeuroscience Innovative Medicines Unit, said the combination of "AstraZeneca'sdeep experience in drug development and translational science with VCNDD'sexpertise in drug discovery is an important step toward bringing new medicinesforward for people who are suffering from neurodegenerative diseases."
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
About the Author
- Jeffrey Bouley
Related Topics
Published In
Volume 9 - Issue 2 | February 2013
February 2013
Loading Next Article...
Loading Next Article...


Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
Subscribe